Review
Nature Reviews Cancer 2, 918-926 (December 2002) | doi:10.1038/nrc951
Focus on: Early detection
Bloodborne biomolecular markers in prostate cancer development and progression
Robert A. Bok1 & Eric J. Small1 About the authors
Abstract
Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.
- View At a Glance
Author affiliations
- Departments of Medicine and Urology, Urologic Oncology Program, Comprehensive Cancer Center, University of California San Francisco, California 94143, USA.
Correspondence to: Robert A. Bok1 Email: bokr@medicine.ucsf.edu
Correspondence to: Eric J. Small1 Email: smalle@medicine.ucsf.edu
